Is Mirikizumab a targeted drug?

Mirikizumab (Mirikizumab)-Omvoh is a targeted biological agent that is an interleukin-23 (IL-23) antagonist. Its mechanism is to selectively bind to the p19 subunit of IL-23, thereby inhibiting its interaction with the IL-23 receptor. This targeting mechanism allows militizumab to effectively reduce the inflammatory response caused by excessive activation of the IL-23 pathway, a process that plays a key role in the development of autoimmune diseases such as ulcerative colitis (UC).

IL-23 is an important cytokine that is closely related to various immune responses. In inflammatory bowel diseases such as ulcerative colitis and Crohn's disease, abnormal expression and activation of IL-23 can lead to an overreaction of the immune system and trigger chronic inflammation of the intestine. These inflammations not only cause obvious discomfort to patients, such as abdominal pain, bloody stools, and urgency to defecate, but may also lead to a significant decrease in health-related quality of life and even cause irreversible intestinal damage. Therefore, drugs targeting IL-23, such as militizumab, are expected to bring new treatment hope to patients by directly intervening in this signaling pathway.

Clinical studies of militizumab have shown promising efficacy in improving symptoms in patients with ulcerative colitis. In patients treated with the drug, levels of inflammatory markers were significantly reduced and clinical symptoms improved significantly. In addition, the safety of militizumab has also been well evaluated. Although the potential risks of infection and other side effects need to be paid attention to when using any biological agent, overall, the incidence of adverse reactions is low.

Reference materials:https://investor.lilly.com/news-releases/news-release-details/lillys-mirikizumab-first-and-only-il23p19-antagonist-report-long